Filtered By:
Vaccination: Measles Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1232 results found since Jan 2013.
A measles virus-based vaccine induces robust chikungunya virus-specific CD4 < sup > + < /sup > T-cell responses in a phase II clinical trial
Vaccine. 2023 Sep 17:S0264-410X(23)01092-7. doi: 10.1016/j.vaccine.2023.09.022. Online ahead of print.ABSTRACTChikungunya virus (CHIKV) is an alphavirus transmitted by mosquitos that causes a debilitating disease characterized by fever and long-lasting polyarthralgia. To date, no vaccine has been licensed, but multiple vaccine candidates are under evaluation in clinical trials. One of these vaccines is based on a measles virus vector encoding for the CHIKV structural genes C, E3, E2, 6K, and E1 (MV-CHIK), which proved safe in phase I and II clinical trials and elicited CHIKV-specific antibody responses in adult measles ser...
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Katharina S Schmitz Anouskha D Comvalius Nella J Nieuwkoop Daryl Geers Daniela Weiskopf Katrin Ramsauer Alessandro Sette Roland Tschismarov Rory D de Vries Rik L de Swart Source Type: research
Baseline immune states (BIS) associated with vaccine responsiveness and factors that shape the BIS
Semin Immunol. 2023 Sep 15;70:101842. doi: 10.1016/j.smim.2023.101842. Online ahead of print.ABSTRACTVaccines are among the greatest inventions in medicine, leading to the elimination or control of numerous diseases, including smallpox, polio, measles, rubella, and, most recently, COVID-19. Yet, the effectiveness of vaccines varies among individuals. In fact, while some recipients mount a robust response to vaccination that protects them from the disease, others fail to respond. Multiple clinical and epidemiological factors contribute to this heterogeneity in responsiveness. Systems immunology studies fueled by advances in...
Source: Seminars in Immunology - September 17, 2023 Category: Allergy & Immunology Authors: Djamel Nehar-Belaid Mark Sokolowski Sathyabaarathi Ravichandran Jacques Banchereau Damien Chaussabel Duygu Ucar Source Type: research
Progress Toward Measles Elimination - African Region, 2017-2021
MMWR Morb Mortal Wkly Rep. 2023 Sep 8;72(36):985-991. doi: 10.15585/mmwr.mm7236a3.ABSTRACTWorldwide, measles remains a major cause of disease and death; the highest incidence is in the World Health Organization African Region (AFR). In 2011, the 46 AFR member states established a goal of regional measles elimination by 2020; this report describes progress during 2017-2021. Regional coverage with a first dose of measles-containing vaccine (MCV) decreased from 70% in 2017 to 68% in 2021, and the number of countries with ≥95% coverage decreased from six (13%) to two (4%). The number of countries providing a second MCV dose ...
Source: MMWR Morb Mortal Wkl... - September 7, 2023 Category: Epidemiology Authors: Balcha G Masresha Cynthia Hatcher Emmaculate Lebo Patricia Tanifum Ado M Bwaka Anna A Minta Sebastien Antoni Gavin B Grant Robert T Perry Patrick O'Connor Source Type: research
Immunogenicity and safety of Mebella ™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study
CONCLUSION: It was concluded from the study results that the test vaccine, Mebella™, was immunogenic and well tolerated and was non-inferior to the comparator vaccine, MR-VAC®, when administered to healthy subjects of 9 months to 49 years of age. Clinical Trial Registry of India Identifier: CTRI/2020/07/026930.PMID:37659893 | DOI:10.1016/j.vaccine.2023.08.065
Source: Vaccine - September 2, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Rahul Jahagirdar Kheya Ghosh Uttam S Srikanth Bhatt S Prashanth Vasudev Rajapantula M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research
Real-world challenges in eligibility for MMR vaccination two years after autologous and allogeneic HSCT
Vaccine. 2023 Aug 29:S0264-410X(23)00778-8. doi: 10.1016/j.vaccine.2023.06.075. Online ahead of print.ABSTRACTMeasles outbreaks have raised concerns of fatal infections in immunocompromised patients. Canadian guidelines advise administration of live vaccines, such as measles, mumps, and rubella (MMR), two yearsafter hematopoietic stem cell transplant (HSCT) yet studies have not assessed eligibility based on medication contraindications. We retrospectively reviewed the charts of 72 autologous (auto-HSCT) and 68 allogeneic (allo-HSCT) recipients at the Windsor Regional Cancer Center to determine MMR reactivity and eligibilit...
Source: Vaccine - August 31, 2023 Category: Allergy & Immunology Authors: Gopika Punchhi Rainbow Negus Hammad Saif Sharon Pritchard Olivia Owen Aman Sehmbi Caroline Hamm Source Type: research
